News Daily News Adult Survivors of Childhood Cancer May Do Well With Simple Strategy for CV Risk Caitlin E. Cox February 13, 2026
News Daily News Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment Yael L. Maxwell January 21, 2026
News Daily News Weight Regained Within 18 Months of Stopping GLP-1 Drugs Michael O'Riordan January 08, 2026
News Daily News Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure Michael O'Riordan December 30, 2025
News Daily News Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION Todd Neale December 16, 2025
News Daily News Chronic Pain Linked to Increased Risk for Incident Hypertension L.A. McKeown November 20, 2025
News Daily News Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension Todd Neale October 07, 2025
News Daily News HYPERION: Sotatercept Helps in PAH Even When Started Earlier in the Disease Todd Neale October 02, 2025
News Daily News Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s Michael O'Riordan September 18, 2025
News Daily News PREVENT Equations in BP Guidelines Means Better Treatment, the ACC/AHA Say Yael L. Maxwell August 28, 2025
News Daily News Self-service Kiosks May Aid Population Monitoring of High BP Todd Neale August 07, 2025
News Daily News Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data L.A. McKeown July 24, 2025
News Daily News AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review Todd Neale July 24, 2025
News Daily News Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050 Todd Neale July 16, 2025
News Daily News Baxdrostat Shows Promise in Uncontrolled or Resistant Hypertension L.A. McKeown July 14, 2025
News Daily News Lorundrostat Lowers BP in Treatment-Resistant Hypertension: Advance-HTN Yael L. Maxwell April 29, 2025
News Daily News FDA Drops REMS Requirement for Antihypertensive Aprocitentan Michael O'Riordan April 09, 2025
News Daily News ‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials Michael O'Riordan February 20, 2025